Look up "immune" on most research catalogs and you find a strange thing: the category is nearly empty. On this one it holds exactly one product. The compounds a researcher would actually reach for when studying immune signaling are filed elsewhere — under healing-recovery, under longevity — because catalog categories track what a compound is studied for rather than what it does.
That would be a trivial filing complaint except for what it hides. The peptides in this space do not share a mechanism, a receptor family, or even a direction of effect. Some are studied for their capacity to raise immune competence. Some are effector molecules that do the killing themselves. Some are studied as brakes. And the two best-characterized members do both, depending on context — which is the single most important thing to understand before reading any of the literature.
The class is a diaspora, not a shelf
Thymosin Alpha-1 is the only catalog entry filed under immune. Pulled in here by mechanism rather than by shelf are LL-37, KPV, VIP and Ara-290 — all catalogued under healing-recovery — plus Thymalin, catalogued under longevity.
One boundary worth setting explicitly: BPC-157 and TB-500 are not in this discussion despite immune-adjacent findings in their preclinical record. Their primary literature is tissue repair, angiogenesis and cytoprotection, and they are covered in the healing-recovery class primer and the tissue-repair roundup.
The useful sort is by which arm of the immune system a compound engages, and which way it pushes.
Direction one: compounds studied as instructors of immune competence
The thymic branch. The thymus is where T-cell precursors are educated, and it involutes with age — the anatomical basis of immunosenescence. Two catalog compounds descend from thymic biology.
Thymosin Alpha-1 is a 28-residue, N-terminally acetylated peptide (Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN) cleaved from the larger precursor prothymosin alpha. Its mechanism is not a classical hormone-receptor story. It has been characterized as engaging Toll-like receptors — principally TLR2 and TLR9 — on dendritic cells, with TLR2 signaling associated with myeloid dendritic cell responses and TLR9 with plasmacytoid dendritic cells. It is best described the way the primary literature describes it: a biological response modifier, a compound that alters how antigen-presenting cells set the tone of a response.
Regulatory status matters here because it is unusual on a research shelf. The synthetic form, thymalfasin (brand name Zadaxin), is registered in a number of countries outside the US for chronic hepatitis B and related indications. It is not FDA-approved. Its recent trial record — including a negative Phase 3 sepsis result — is covered in the immune-modulating peptides roundup.
Thymalin shares the thymic origin and almost nothing else. It is not a defined molecule. It is a polypeptide fraction extracted from thymus tissue, studied largely within a single Russian research lineage for immune restoration in aging — the same single-lineage evidence caveat that applies to Epithalon, discussed in the longevity class primer. The fraction-versus-molecule distinction has direct consequences for documentation, covered below.
Direction two: compounds that are themselves the effector
LL-37 is categorically different from everything else here. It does not instruct a cell to do something. It is the thing that does it.
LL-37 is the only human cathelicidin. It is stored as an inactive precursor, hCAP18, and released by proteolytic cleavage — proteinase 3 in neutrophils, kallikreins in keratinocytes — into a 37-residue cationic, amphipathic α-helix. That physical chemistry is the mechanism: a positively charged helix with a hydrophobic face associates with negatively charged bacterial membranes and disrupts them. The same electrostatics let it bind and neutralize lipopolysaccharide, blunting endotoxin signaling.
It also has a signaling life. LL-37 acts as a chemoattractant for leukocytes, with formyl peptide receptor 2 (FPR2) among the receptors implicated. So it sits across two mechanistic descriptions at once — a direct antimicrobial agent and an immune signaling molecule — which is exactly the sort of dual identity that makes single-sentence summaries of this class unreliable.
The two best-studied members point both ways
This is the part that a three-bucket sort would obscure, and it is the most useful thing in the category.
Thymosin Alpha-1 has a tolerance program, not just an activating one. Work by Romani and colleagues (2006; PubMed 16741252) reported that the peptide activates dendritic cell tryptophan catabolism via indoleamine 2,3-dioxygenase (IDO) in a manner requiring TLR9 and type I interferon receptor signaling, with downstream IL-10 production and generation of regulatory T cells. The paper's own framing is instructive: it establishes "a regulatory environment for balance of inflammation and tolerance." A compound routinely described as an immune stimulant has a well-documented arm that generates Tregs.
LL-37 has an autoimmunity arm. Lande and colleagues (Nature 2007;449:564–569) showed that LL-37 complexes with extracellular self-DNA, condensing it into aggregates retained in early endosomes of plasmacytoid dendritic cells, where it triggers TLR9 and drives interferon production — converting inert self-DNA into an immune trigger. This is a central mechanism in psoriasis research. Follow-up work extended it to self-RNA complexes signaling through TLR7 and TLR8 (2009), and a 2014 Nature Communications paper identified LL-37 itself as a T-cell autoantigen in psoriasis.
So the endogenous peptide that neutralizes bacterial endotoxin is also the one implicated in breaking tolerance to host nucleic acid. Direction of effect here is a property of context — concentration, tissue, what else is present — not an intrinsic property of the molecule. "Immune booster" is not so much wrong as unresolvable.
Direction three: brakes and resolution
Three compounds are studied primarily for dampening inflammatory signaling, by three unrelated routes.
KPV is the C-terminal tripeptide of α-MSH (Lys-Pro-Val). The foundational reference is Dalmasso and colleagues, Gastroenterology 2008, "PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation": KPV is taken into intestinal epithelial and immune cells by the di/tripeptide transporter PepT1, and inside the cell has been reported at nanomolar concentrations to inhibit NF-κB and MAP kinase inflammatory signaling with reduced proinflammatory cytokine output. In murine colitis models, orally administered KPV reduced disease incidence.
The mechanistically important detail: although KPV is a melanocortin fragment by lineage, its anti-inflammatory effect is not dependent on melanocortin receptor signaling. It is a transporter-delivered intracellular actor, not an MC-receptor agonist. Compare the receptor-level picture in the melanocortin system explainer.
VIP is a 28-residue neuropeptide acting on VPAC1 and VPAC2, class B G-protein-coupled receptors shared with PACAP. Its research literature spans vasodilation, neuroprotection and immune regulation including regulatory T-cell effects. Its defining practical problem is pharmacokinetic: plasma half-life is reported on the order of about a minute. Any research use is a delivery problem before it is a pharmacology problem — see the PK primer.
Ara-290 (cibinetide) is an 11-residue peptide engineered from the helix B region of erythropoietin. The design premise is receptor separation: erythropoietin's tissue-protective signaling is attributed to an "innate repair receptor," described as a heterodimer of the EPO receptor with the beta-common receptor (CD131), distinct from the homodimeric EPOR that drives red blood cell production. Ara-290 was built to engage the former without the latter.
Two caveats belong with that. First, the IRR framing originates substantially with Brines, Cerami and Araim Pharmaceuticals — the developing group — and the same single-research-lineage caution applied elsewhere on this site to BPC-157 and Thymalin applies here. Second, Ara-290's clinical file, including a met Phase 2b endpoint in sarcoidosis-associated small-fiber neuropathy and the program's subsequent stranding, is covered in the immune roundup.
Receptor architecture: the widest spread on any shelf
No other catalog category contains this much structural variety in how a compound reaches its target:
- Pattern-recognition receptors — Thymosin Alpha-1 at TLR2/TLR9, an innate-immunity sensor family, not a hormone receptor
- Class B GPCR — VIP at VPAC1/VPAC2, the same architecture as the GLP-1 and GHRH receptors
- A heterodimer distinct from its own parent hormone's homodimer — Ara-290 at the proposed EPOR/CD131 complex
- No receptor at all — KPV, taken up by a transporter and acting on an intracellular signaling node
- The membrane itself — LL-37's direct antimicrobial action is physical chemistry, not receptor binding
The receptor pharmacology primer makes the general point that "the receptor is not always one protein." Ara-290 is a cleaner case of it than the amylin example used there, and KPV joins FOXO4-DRI in the small set of catalog compounds with no receptor in the mechanism at all.
What a purity number can and cannot mean here
This class carries a documentation problem that most do not.
Thymalin is a heterogeneous fraction. Its listed specification says so directly — a mixture of thymic polypeptides, not a single sequence. A purity percentage of a mixture is not a characterization number. It cannot be, in the way it is for a defined synthetic peptide: there is no single correct species for the other components to be impurities of. This is the same principle that governs HMG and HCG, where potency is assigned by bioassay against a reference standard precisely because the active species is a mixture. Its absence there is not a red flag; its presence here without explanation is a template artifact.
Three more route-specific points:
- Thymosin Alpha-1 is N-terminally acetylated. That is +42 Da on the intact mass. A COA mass must correspond to the acetylated peptide, and the des-acetyl species is a near-mass impurity worth knowing exists.
- LL-37 binds LPS — which is useful biology and an analytical nuisance, because it can interfere with LAL endotoxin testing. Positive product controls exist for exactly this; see the endotoxin testing piece.
- VIP carries a methionine at position 17, making it oxidation-prone. That is a stability question rather than a synthesis one — see peptide degradation pathways.
Full documentation standards are at our quality page, and compound-level detail is in the library.
FAQ
Is there a single "immune peptide" mechanism? No. The compounds discussed here engage Toll-like receptors, a class B GPCR, a proposed cytokine-receptor heterodimer, an intracellular transcription factor pathway, and bacterial membranes directly. The category names a research question, not a mechanism.
Why are LL-37, KPV, VIP and Ara-290 filed under healing-recovery? Because their most-developed research literature is in inflammation and repair contexts. Filing follows the studied application. It does not follow the pathway, which is why reading by mechanism gives a different and more useful map.
Which member has the strongest human evidence? Thymosin Alpha-1, by a wide margin — it is registered in multiple countries and has a substantial trial record, including recent negative results. Ara-290 has completed clinical work; VIP has Phase 2 data; LL-37, KPV and Thymalin remain preclinical or thinly evidenced in humans. As always, adjacency in a catalog implies nothing about evidence maturity.
This article is educational and for the laboratory research community. Trulogic Labs products are sold for laboratory and research use only and are not for human consumption.